Daniel Skiest to Anti-HIV Agents
This is a "connection" page, showing publications Daniel Skiest has written about Anti-HIV Agents.
Connection Strength
2.077
-
Iarikov DE, Irizarry-Acosta M, Martorell C, Hoffman RP, Skiest DJ. Low prevalence of primary HIV resistance in western Massachusetts. J Int Assoc Physicians AIDS Care (Chic). 2010 Jul-Aug; 9(4):227-31.
Score: 0.315
-
Skiest DJ, Krambrink A, Su Z, Robertson KR, Margolis DM. Improved measures of quality of life, lipid profile, and lipoatrophy after treatment interruption in HIV-infected patients with immune preservation: results of ACTG 5170. J Acquir Immune Defic Syndr. 2008 Dec 01; 49(4):377-83.
Score: 0.282
-
Iarikov D, Duke W, Skiest D. Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndrome. AIDS Read. 2008 Oct; 18(10):524-7.
Score: 0.279
-
Skiest DJ, Su Z, Havlir DV, Robertson KR, Coombs RW, Cain P, Peterson T, Krambrink A, Jahed N, McMahon D, Margolis DM. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis. 2007 May 15; 195(10):1426-36.
Score: 0.252
-
Skiest DJ, Morrow P, Allen B, McKinsey J, Crosby C, Foster B, Hardy RD. It is safe to stop antiretroviral therapy in patients with preantiretroviral CD4 cell counts >250 cells/microL. J Acquir Immune Defic Syndr. 2004 Nov 01; 37(3):1351-7.
Score: 0.213
-
Skiest DJ, Crosby C. Survival is prolonged by highly active antiretroviral therapy in AIDS patients with primary central nervous system lymphoma. AIDS. 2003 Aug 15; 17(12):1787-93.
Score: 0.196
-
Namazi G, Fajnzylber JM, Aga E, Bosch RJ, Acosta EP, Sharaf R, Hartogensis W, Jacobson JM, Connick E, Volberding P, Skiest D, Margolis D, Sneller MC, Little SJ, Gianella S, Smith DM, Kuritzkes DR, Gulick RM, Mellors JW, Mehraj V, Gandhi RT, Mitsuyasu R, Schooley RT, Henry K, Tebas P, Deeks SG, Chun TW, Collier AC, Routy JP, Hecht FM, Walker BD, Li JZ. The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis. 2018 11 05; 218(12):1954-1963.
Score: 0.141
-
Strongin Z, Sharaf R, VanBelzen DJ, Jacobson JM, Connick E, Volberding P, Skiest DJ, Gandhi RT, Kuritzkes DR, O'Doherty U, Li JZ. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA. J Virol. 2018 06 15; 92(12).
Score: 0.136
-
Skiest DJ, Hester LJ, Hardy RD. Cryptococcal immune reconstitution inflammatory syndrome: report of four cases in three patients and review of the literature. J Infect. 2005 Dec; 51(5):e289-97.
Score: 0.057
-
Skiest DJ. The importance of co-morbidity in older HIV-infected patients. AIDS. 2003 Jul 04; 17(10):1577.
Score: 0.049
-
Keiser P, Nassar N, Skiest D, Andrews C, Yazdani B, White A, Hetherington S. Comparison of symptoms of influenza A with abacavir-associated hypersensitivity reaction. Int J STD AIDS. 2003 Jul; 14(7):478-81.
Score: 0.048
-
Sharaf R, Lee GQ, Sun X, Etemad B, Aboukhater LM, Hu Z, Brumme ZL, Aga E, Bosch RJ, Wen Y, Namazi G, Gao C, Acosta EP, Gandhi RT, Jacobson JM, Skiest D, Margolis DM, Mitsuyasu R, Volberding P, Connick E, Kuritzkes DR, Lederman MM, Yu XG, Lichterfeld M, Li JZ. HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers. J Clin Invest. 2018 08 31; 128(9):4074-4085.
Score: 0.035
-
Keiser P, Rademacher S, Smith J, Skiest D. G-CSF association with prolonged survival in HIV-infected patients with disseminated Mycobacterium avium complex infection. Int J STD AIDS. 1998 Jul; 9(7):394-9.
Score: 0.034
-
Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, Badley AD. Investigation of Efavirenz Discontinuation in Multi-ethnic Populations of HIV-positive Individuals by Genetic Analysis. EBioMedicine. 2015 Jul; 2(7):706-12.
Score: 0.028
-
Goldman M, Zackin R, Fichtenbaum CJ, Skiest DJ, Koletar SL, Hafner R, Wheat LJ, Nyangweso PM, Yiannoutsos CT, Schnizlein-Bick CT, Owens S, Aberg JA. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis. 2004 May 15; 38(10):1485-9.
Score: 0.013